VAXIL COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT

Ads

You May Also Like

aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports ...

Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS

Pharmacokinetic Bioequivalence Shown for Cytori’s ATI-0918 Liposomal Formulation of Doxorubicin Hydrochloride, Results Presented at ...